13D Filing From Biotechnology Value Fund On Oncothyreon Reveals 19.8% Stake

Shares of

, a small cap biopharmaceutical company, spiked higher by 10 percent early Monday morning after Biotechnology Value Fund reported a 19.8 percent stake in the company in a 13-D filing.

is a private investment partnership that specializes in "fundamentally-driven public biotechnology investments." According to the 13-D filing, "BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 18,799,368 Shares beneficially owned by Partners, excluding 5,000,000 Shares issuable upon the exercise of certain Warrants, 7,500,000 Shares issuable upon the exercise of certain Series C Convertible Preferred Stock, 5,333,000 Shares issuable upon the exercise of certain Series B Convertible Preferred Stock and 2,500,000 Shares issuable upon the exercise of certain Series A Convertible Preferred Stock, representing percentage ownership of approximately 19.8 percent of the Shares outstanding." Shares of Oncothyreon have gained more than 15 percent since the start of 2015 but have lost more than 30 percent over the past month.